Axiom™ PharmacoPro™ SwiftArray™ Kit

The Axiom PharmacoPro SwiftArray Kit provides a complete microarray solution for pharmacogenomic research, including all necessary array plates, reagents, controls, and consumables to process up to 94 samples and 2 controls in a single run. Designed for translational and preclinical research, this kit helps researchers investigate how genetic variation influences drug response and metabolism.

The PharmacoPro kit enables comprehensive screening of key ADME (absorption, distribution, metabolism, and excretion)-relevant genetic variants using a high-throughput microarray workflow compatible with automated instrumentation.

Features of the Axiom PharmacoPro Array include:

• 4,627 markers in 1,191 genes of known pharmacogenomic value, including Phase I and Phase II enzymes, regulatory/modifier genes, drug target genes, and Phase III/transporter genes
• Genotyping of highly predictive markers in genes, including GSTM1, CYP1A2, CYP2D6, CYP2B6, CYP2A6, SULT1A1, CYP2C19, and CYP2C9, that are in highly homologous regions
• CNV analysis for copy number states ranging from zero to three-plus for important ADME genes
• Star allele and translation for key genes

Array content

The PharmacoPro solution broadly screens for pharmacogenomic risk factors for research and leverages content carefully selected from top global consortia (see figure below).

• Core functional pharmacogenomic content including markers from Clinical Pharmacogenomics Implementation Consortium (CPIC) guidelines
• Pharmacogenomics Knowledgebase (PharmGKB) markers in Very Important Pharmacogenes (VIP)
• PharmGKB markers with clinical annotations
• PharmaADME core markers
• Nearly all markers from DMET Plus Solution (1,936 genetic variants across 231 relevant genes)
• Human leukocyte antigen (HLA) markers associated with drug reactions
• Markers for killer cell immunoglobulin-like receptors (KIR), human ancestry identification, and sample ID and tracking
• Pharmacogenetics/ADME markers in genes targeted for European populations drawn from UK Biobank Axiom Array

Continuity of content for cohort studies and clinical trials

Drug development research and clinical trials are typically conducted over several years. These long-term efforts require a platform that can guarantee multiyear availability of 100% of the specific array content for the entire timeline of initiative. Unlike bead-based technologies that experience batch-to-batch variability and single nucleotide polymorphism (SNP) dropouts with each manufacturing batch, the photolithography manufacturing technology used in the PharmacoPro array guarantees 100% fidelity and ensures all markers are present on every manufacturing batch for as long as necessary, addressing a major concern for such long-term efforts.